*Applications will be reviewed on a rolling- basis.
A research opportunity is available in the Office of Surveillance and Epidemiology/Office of Medication Error Prevention and Risk Management, Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA) located in Silver Spring, Maryland. CDER performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. As part of the FDA, CDER regulates over-the- counter and prescription drugs, including biological therapeutics and generic drugs. This work covers more than just medicines.
This project will contribute to the regulatory science of medication error prevention and analysis by applying training, learning and experience gained at the Institute for Safe Medication Practices (ISMP) and the FDA in the prevention or mitigation of medication errors. Under the guidance of a mentor, the participant will complete formal training in Root Cause Analysis (RCA), Failure Mode and Effects Analysis (FMEA) and other risk-assessment; as well as review medication error reports and complete research related to drug nomenclature, packaging, labels and labeling, or human factors.
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.